1	Title
2	
3	Large-scale blood mitochondrial genome-wide study provides novel insights into mitochondrial
4	disease-related traits
5	
6	Authors
7	
8	Cannon S <sup>1*</sup> , Hall T <sup>1*</sup> , Hawkes G <sup>1*</sup> , Colclough K <sup>2</sup> , Boggan RM <sup>3</sup> , Wright CF <sup>1</sup> , Pickett SJ <sup>3</sup> , Hattersley AT <sup>1</sup> ,
9	Weedon MN <sup>1</sup> , Patel KA <sup>1</sup>
10	Affiliations
11	<sup>1</sup> Department of Clinical and Biomedical Sciences, University of Exeter Medical School, RILD building,
12	Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
13	<sup>2</sup> Exeter Genomics Laboratory, Royal Devon University Healthcare, RILD
14	<sup>3</sup> Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute,
15	Newcastle University
16	
17	*Equal contribution
18	
19	Corresponding authors
20	Dr Kashyap A Patel
21	Department of Clinical and Biomedical Sciences, University of Exeter Medical School, RILD building,
22	Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
23	
24	Email : <u>K.A.Patel@exeter.ac.uk</u>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 25 Abstract

26

Background/Objectives: Whole genome sequencing (WGS) from large cohorts enables the study of
 mitochondrial DNA (mtDNA) variation on human health. We aimed to investigate the influence of
 common, rare, and pathogenic mtDNA variants on 15 mitochondrial disease-related phenotypes.

31 Methods: Using WGS from 179,862 individuals from in the UK Biobank, we identified mtDNA 32 variants using MitoHPC. We performed extensive association analyses with 15 mitochondrial 33 disease-relevant phenotypes. We compared the results for the m 22424>G variant with those from the second second

disease-relevant phenotypes. We compared the results for the m.3243A>G variant with those from a

34 clinically referred patient cohort.

35

36 Results: Of 15,881 mtDNA variants, 12 homoplasmic and one heteroplasmic variant had genome-37 wide significant associations. All homoplasmic variants increased aspartate aminotransferase level 38 and three were novel, low frequency, variants (MAF~0.002 and beta~0.3 SD). Only m.3243A>G (MAF=0.0002) associated with diabetes (OR=5.6, 95%CI [3.2-9.9]), deafness (OR=12.3, 95%CI [6.2-39 40 24.4]) and heart failure (OR=39.5, 95%CI [9.76-160.1]). Multi-system disease risk and penetrance of 41 all three traits increased with m.3243A>G level. Diabetes risk was further influenced by common 42 nuclear genome variation. The penetrance of diabetes with m.3243A>G in the UK Biobank was lower 43 than clinically referred patients, partly attributed to lower heteroplasmy. Of 73 pathogenic 44 mitochondrial disease variants, most were rare in the population with low penetrance. 45 Conclusion: Our study highlights the utility of WGS for investigating mitochondrial genetics within a 46 47 large, unselected population. We identified novel associations and demonstrated that pathogenic mitochondrial variants have lower penetrance in clinically unselected than clinically referred 48 49 settings. m.3243A>G associated with mitochondrial-related phenotypes at higher heteroplasmy. Our 50 findings suggest potential benefits of reporting incidentally identified m.3243A>G at high

51 heteroplasmy levels.

52

# 53 Introduction

- 54 Mitochondrial function is fundamental to human life but can be impaired by pathogenic
- 55 mitochondrial (mt)DNA variants, leading to disease with variable expressivity and penetrance (1, 2,
- 56 3). Studies of predominantly clinically ascertained cohorts have identified >90 pathogenic variants in
- 57 the mitochondrial genome (1, 2, 4, 5). These variants cause rare heterogeneous mitochondrial
- 58 disorders, including complex multi-organ disease (1). Multiple studies have also reported mtDNA
- 59 variants associated with complex diseases such as maternally-inherited diabetes (6), metabolic
- diseases (7, 8), Parkinson disease (9), neuroticism (10), as well as stroke and psoriasis (11), among
- others. These variants provide insight into the function of human mitochondria and the
- 62 pathogenesis underlying these diseases (12).

63 Previous mitochondrial DNA studies have had limitations. For example, when identifying

64 mitochondrial variants which affect complex traits, studies have either assessed a subset of common

variants (n~700) in large, unselected cohorts (13, 14), or all variants in small, often clinically selected

66 cohorts (n=100-2800) focussing on a certain phenotype (15, 16). Studies of pathogenic variants have

67 been primarily restricted to patients and family members with certain phenotypes, likely resulting in

68 over-inflated penetrance and expressivity estimates as seen for nuclear pathogenic variants (17, 18,

- 69 19). Large-scale rare and common mitochondrial genome-wide association studies in clinically
- vunselected populations can overcome these limitations, and lead to novel insights into the impact of
- 71 mitochondrial variants on human health (20).
- 72 The recent availability of whole genome sequencing data (WGS) from large cohorts provides a

via unique opportunity to study rare and common mitochondrial variants. WGS data have recently been

made available in large population cohorts such as the UK Biobank (UKB, n=200,030) (21) and All of

- 75 Us (22). WGS captures information from both mitochondrial DNA (mtDNA) and nuclear DNA,
- providing high-quality genotyping for all mitochondrial variations, both rare and common.

77 Importantly, it also provides accurate data on variant heteroplasmy (proportion of mtDNA molecules

- with alternate allele) and mtDNA copy number (mtCN), making it an ideal technology to study all,
- and particularly rare, heteroplasmic and homoplasmic mitochondrial variation (23). These large
- 80 cohort studies also provide excellent opportunity to assess penetrance and expressivity of known
- 81 pathogenic variants in a clinically unselected population which is crucial before considering the
- 82 incidental reporting of mitochondrial variants.

- 83 Here we use WGS data from a large multi-ethnic population cohort of 200,030 individuals from the
- 84 UKB. We aimed to identify novel rare and common variants associated with 15 common
- 85 mitochondrial disease-related traits and assess the prevalence and penetrance of known pathogenic
- 86 variants in an unselected population cohort.

# 87 Methods

#### 88 Study subjects

89 UK biobank

- 90 The UKB is an ethically-approved population cohort of ~500,000 individuals from the UK (24). The
- 91 UKB contains deep phenotype data from self-reporting, hospital and GP records, and measurements
- 92 of 30 blood biomarkers including HbA1c and liver enzymes, which are paired with detailed genetic
- 93 data. Whole exome sequencing and genotyping array imputation data are available in the entire
- 94 cohort, and at the time of writing (May 2023). WGS data is available on 200,030 participants of
- 95 diverse genetic ancestries. The lack of selection on any specific disease phenotypes, and large
- 96 sample size, makes it an ideal cohort to study rare genotype-phenotype associations. Cohort
- 97 characteristics of individuals included in the current study are summarised in Table S1.
- 98
- 99 Clinically identified probands with m.3243A>G pathogenic variant
- 100 We included 95 probands who were referred from routine diabetes clinics in the UK to Exeter
- 101 Genomics laboratory, Royal Devon University Healthcare Hospital with suspected mitochondrial-
- related diabetes and found to harbour the m.3243A>G variant. The study was approved by the
- 103 Wales Research ethics Committee 5 (22/WA/0268). Cohort characteristics for these individuals are
- summarised in Table S2.
- 105

#### 106 *Clinical phenotypes*

- 107 We analysed 15 diseases/traits that have been commonly associated with mitochondrial disease (1)
- 108 (25) and were possible to generate from the data available in the UKB. We used self-report data,
- 109 ICD9/10 codes, medication, and biomarkers to find these phenotypes (Table S3).

110

#### 111 Genetic data

#### 112 Whole genome sequencing data

- 113 UKB generated WGS alignment files (CRAM format) using the deCODE pipeline as previously
- described (21). Briefly, 500ng of genomic DNA per-sample underwent paired-end sequencing of 150
- base pairs on Illumina NovaSeq6000 sequencers with the S4 flow cell and real time base calling. Data

116 were aligned to GRCh38 before undergoing contamination and data quality control. A detailed

- 117 description is available from webpage
- 118 <u>https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=180</u>. We derived genetic ancestry for
- 119 Europeans (EUR-like), Africans (AFR-like) and South Asians (SAS-like) via comparison of genotypes
- 120 derived from the UK Biobank Axiom Array to nuclear genome principal components derived from the
- 121 1000 genomes project.
- 122
- 123 Mitochondrial variant calling from whole genome sequencing data
- 124 We used MitoHPC with Mutect2 in mitochondrial mode to acquire mitochondrial variants from the
- 125 WGS CRAM files of the 200,030 participants (26) (27). MitoHPC is specifically designed to detect
- 126 mitochondrial single nucleotide variants (SNV) in large WGS datasets and provides accurate
- 127 heteroplasmy estimates by using a consensus mitochondrial sequence for each sample. MitoHPC
- also provides mitochondrial copy number estimation (as a proportion of reads mapped to the
- 129 mitochondrial and nuclear genomes), haplogroup determination, sequencing coverage statistics, as
- 130 well as quality metrics at both sample and variant levels.
- 131
- 132 We used stringent sample exclusion criteria to minimise false-positive low heteroplasmic variant
- 133 calls. We excluded potentially contaminated samples (e.g. multiple dominant haplogoups in a single
- sample n=736), samples with low coverage (min <200x or mean <500x, n=1126), or samples with
- 135 multiple nuclear DNA of mitochondrial origin (nuMT) variants flagged by MitoHPC (n=17,485) (26).
- 136 Extremes of mitochondrial copy number (Q1-1.5xIQR and Q3+1.5xIQR, n=13), were also excluded.
- 137 An additional 821 samples were excluded where low quality, or missing, genotype data excluded
- 138 them from the generation of a genetic relatedness matrix (n=731) or were not able to be processed
- by MitoHPC (n=90). In total, Of the 199,209 samples that were processed by MitoHPC, 179,862
- 140 (90.3%) samples passed our robust sample filtering.
- 141

Our variant level filtering was in line with previous large studies (20). Specifically, we removed low quality variants identified by GATK FilterMutectCalls as well as multiallelic indels and those identified within six known low complexity regions (20) or at 382 nuMT sites determined by MitoHPC (26). This provided us with 15,881 variants in 179,862 individuals. Of these, 12,009 (~76%) variants had a minor allele frequency <0.01% which would not have been reliably captured using genotyping array technology (28) and 8,896 variants (56%) had minor allele count (MAC) ≥5. Given our stringent filtering criteria, our primary analysis used variants with ≥3% heteroplasmy. We also performed

sensitivity analysis for variants with  $\geq$ 5% and  $\geq$ 10% heteroplasmy, as shown in Table 1, to remove

150	the possible false association b	y low level mitochondrial heteroplasmic calls.
-----	----------------------------------	--

151

Definition	Reference genotype	Heteroplasmic	Homoplasmic
Primary	<3	≥3 and <97	≥97
Sensitivity	<5	≥5 and <95	≥95
Sensitivity	<10	≥10 and <90	≥90

Table 1 – Heteroplasmy (%) thresholds used to define heteroplasmic and homoplasmic variants.

154 Type 2 Diabetes (T2D) genetic risk score

155 We generated a T2D genetic risk score for individuals in the UKB based on 88 T2D associated

variants from genotyping array as identified in previous genome wide association studies (29) (30)

157 that did not include the UKB. We also generated the partitioned T2D scores as described by Udler *et* 

158 al. (2018)(31).

159

# 160 m.3243A>G testing for clinically referred probands

We used digital droplet PCR (ddPCR) on a Bio-Rad (California, USA) machine to analyse blood DNA for presence of and to determine heteroplasmy of m.3243A>G. PCR primer sequences for the m.3243A>G ddPCR assay are described by Singh *et al* (2006)(32). Plates were run on an AutoDG Droplet Generator (Bio-Rad) with DG32 cartridges according to manufacturer's instructions and analysed using QuantaSoft version 1.7 software (Bio-Rad). All samples were tested in triplicate and droplet data combined for final analysis of heteroplasmy. Heteroplasmy >2% was considered positive.

167

168 List of Known pathogenic mitochondrial variants

169 We reviewed all proposed pathogenic variants from the MitoMAP repository (accessed Oct 2022)

170 <u>https://mitomap.org/foswiki/bin/view/MITOMAP/ConfirmedMutations</u>. For this study, we included

a variant (n=73, Table S4) if it is curated as pathogenic or likely pathogenic based on the multiple

- 172 MitoMAP criteria (status = Cfrm)
- 173 (<u>https://www.mitomap.org/foswiki/bin/view/MITOMAP/MutationsCodingControlCfrm</u>) and where available,
- 174 annotated as pathogenic or likely pathogenic based on the independent criteria defined by the
- 175 international ClinGen consortium e.g. <u>https://mitomap.org/cgi-bin/search\_allele?variant=7445A>G</u>.
- 176

# 177 Statistical analysis

178 Mitochondrial genome wide association

We performed single variant association analysis for variants with a MAC ≥5 (n=8,896) using
REGENIE (v3.1.4) (33) for 15 selected disease/traits (Table S3). REGENIE performs genome wide
association testing for large sample sizes and is robust to unbalanced case-control ratios, and
controls for population structure by utilising a genetic relatedness matrix generated from common,
independent nuclear single nucleotide polymorphisms. To generate the genetic relatedness matrix,
we used participants who had both a whole genome sequence and whole exome sequence data
available.

186

187 For variants which were only ever heteroplasmic, or only ever homoplasmic in our cohort, we 188 compared them against the reference genotypes. For variants where some individuals were defined 189 as heteroplamic and some homoplasmic, our primary comparison was individuals with homoplasmic 190 variant versus individuals with heteroplasmic or reference genotype. We performed secondary 191 analysis by comparing heteroplasmic or homoplasmic variant genotypes together versus reference 192 genotypes. We rank inverse normalised the continuous traits and the analysis was adjusted for age 193 at recruitment, sex, sequencing batch, recruitment centre, mitochondrial copy number (mtCN) and 194 the first 40 nuclear genetic principal components (PC). Our significance threshold was the Bonferroni 195 corrected p value of  $<3.75 \times 10^{-7}$  calculated by number of variants and traits that were analysed 196 (=0.05/8896/15).

197

### 198 Rare variant aggregation testing

We performed aggregate testing of rare mtDNA variants (MAF<0.1%) annotated as either missense,</li>
synonymous, or loss-of-function by Ensembl VEP (34) which were grouped by mitochondrial
transcript, the d-loop, and 100bp sliding windows at 10bp intervals. Previously known pathogenic
variants were also grouped by their known disease phenotypes (Table S4). We used REGENIE to
perform burden, SKAT and ACAT aggregate tests (33) for association with all 15 traits. We used a
Bonferroni corrected p value of <2x10<sup>-6</sup> as our significance threshold, calculated by number of masks
and traits that were analysed (=0.05/1696/15).

206

#### 207 Penetrance of diabetes for m.3243A>G

208 We used Kaplan-Meier survival estimates to estimate the age-dependent penetrance of diabetes. A

log-rank test for equality was used to compare the penetrance of diabetes between the groups.

210 Cox's regression was used to compute the hazard ratio for developing diabetes with or without the

adjustment of covariates. The analysis included all individuals without diabetes and individuals with

diabetes without missing age at diagnosis (92% of all diabetes cases). We used STATA 16 for all

analysis.

214

## 215 **Results**

#### 216 Mitochondrial-wide single variant association identified associations with diabetes, deafness,

#### 217 heart failure and aspartate aminotransferase.

- 218 We performed single variant association analyses for 8,896 mitochondrial variants (MAC ≥ 5) with 15
- 219 disease/traits that are commonly reported in individuals with mitochondrial disease (Tables S3, S5).
- 220 In a European-like ancestry analysis, we identified four disorder/traits where variants were
- associated at our Bonferroni-corrected significance threshold (p<3.75x10<sup>-7</sup>) of which enzyme
- aspartate aminotransferase (AST) was the only trait with >1 variant association. This included 12
- homoplasmic variants associated with AST and only one heteroplasmic variant (m.3243A>G)
- associated with diabetes (MAF=0.00024, OR=5.6, 95% CI [3.2-9.9], P=4x10<sup>-9</sup>) and hearing aid use
- 225 (OR=12.3, 95% CI [6.2-24.4], P=6x10<sup>-13</sup> Figure 1A, Table S6). Sensitivity analysis using a higher
- 226 heteroplasmy threshold (≥10%) observed one additional association of heart failure with the same
- 227 m.3243A>G variant (OR=39.5, 95% CI [9.76-160.1]; P<3x10<sup>-7</sup>; Table S5). Sensitivity analysis using the
- 228 dominant model of association (reference vs either heteroplasmic or homoplasmic) did not identify

additional variants and showed consistent results.





- Bonferroni-corrected significance threshold (P<4.03x10<sup>-7</sup>). R<sup>2</sup> Correlation is relative to the most significant
- variant in each plot. **B** Forest plot of *m.3243A>G* associations at increasing minimum heteroplasmy. Solid
- points denote associations passing the Bonferroni significance threshold (P<3.75x10<sup>-7</sup>). Heart failure (all-cause)

was the only phenotype to have a significant association in the sensitivity tests for any traits. AST=aspartatetransferase.

239

# Lead AST associated variant associates with other liver enzymes but not non-alcoholic fatty liverdisease

242 Of the 12 primarily homoplasmic variants associated with increased AST levels, three were low 243 frequency novel variants with a large effect size (MAF  $\sim 0.002$ ,  $\beta \sim 0.33$ ) compared to previously 244 known variants (Figure 1, Tables S5, S6, S7). The conditional analysis of each variant for all others showed that the AST associations were led by one previously reported variant: m.15758A>G 245 246  $(MAF=0.02; \beta=0.09, P=5x10^{-8})$  (13) and one novel variant: m.13488C>T (MAF=0.002;  $\beta=0.33, P=7x10^{-1}$ <sup>11</sup>) (Table S6). m.15758A>G causes a missense change in the MY-CYB gene and m.13488C>T is a 247 248 synonymous change in the MT-ND5, both components of respiratory chain complexes. We next 249 tested the association of these two lead variants with four other liver biomarkers; alanine 250 aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin 251 and, non-alcoholic fatty liver disease (NAFLD). Both these variants associated with increased 252 ALT (beta 0.06 and 0.24 respectively, p<6x10<sup>-4</sup>) but neither were associated with any other liver 253 markers or non-alcoholic fatty liver disease (Table S8).

254

## 255 Rare variant aggregation and other ancestry analyses did not identify additional novel associations

256 We next performed rare variant (MAF < 0.001) aggregation burden analyses to determine whether

rare mtDNA variants were associated with these mitochondrial-related traits. We aggregated rare

variants by mitochondrial transcript and for 100bp sliding windows at 10bp intervals. We did not

identify any new associations at a Bonferroni-corrected P value ( $2x10^{-6}$ ; =0.05/1696/15). We did

260 not identify single or rare variant aggregated associations in an analysis of African-like or South

Asian-like ancestry individuals at Bonferroni corrected significance threshold.

262

# The m.3243A>G association with diabetes, deafness, and heart failure greatly increases with blood heteroplasmy ≥10%

The variant m.3243A>G was associated with diabetes and deafness at ≥3% heteroplasmy and these

associations were stronger with higher heteroplasmy. The median m.3243A>G heteroplasmy was

267 7.8% (IQR 5.3-13.1%) for 83 m.3243A>G carriers (all ancestry) in the UKB. Of which, 23% had 3-4.9%,

268 47% had 5-9.9% and 30% had ≥10% (Figure S1). Consistent with cross-sectional analysis, we

269 observed higher age-related penetrance of diabetes using Cox proportional hazard model for diabetes (HR 5.8, 95% CI: [3.8-9], p=3.5x10<sup>-15</sup>) in all m.3243A>G carriers compared to non-carriers 270 271 (Figure S2). Although, the overall risk was higher, this was predominantly driven by individuals with 272 heteroplasmy  $\geq$ 5% (Figure 2A, Table S9). The risk of diabetes was similar to the background/non 273 m.3243A>G carriers for individuals with m.3243A>G heteroplasmy of 3-4.9% (HR 0.98, 95% CI [0.14-274 6.9], p>0.9) but increased to 3.8 (95% CI [1.8-8], P=3.9x10<sup>-4</sup>) for 5-9.9%, and further increased to 20.6 275 (95% CI [11.7-36.4], P=1.2x10<sup>-25</sup>) for individuals with ≥10% (Table S9) (P heterogeneity=0.0001). Of 276 the 16,386 individuals with diabetes, m.3243A>G was responsible for 0.14% of diabetes. All results 277 were consistent for unrelated European-like ancestry individuals and when using tertiles of age-278 adjusted m.3243A>G heteroplasmy (based on a previously published formula (35)) (Figure S3A, Table 279 S10). These data suggest that m.3243A>G level in the blood is an important factor underlying 280 penetrance in a clinically unselected population.

281

# m.3243A>G is associated with higher risk of multisystem disorder which increases with higher heteroplasmy.

284 The variant m.3243A>G is commonly associated with a multi-system disorder when ascertained 285 clinically. It is not clear if this occurs when assessed in a hypothesis-free manner in clinically 286 unselected cases, and whether any risk is affected by m.3243A>G levels. To assess this, we grouped 287 mitochondrial-related disorders where we observed the nominal association with m.3243A>G at 288 p<0.05 into seven anatomical sites. For example, cardiovascular disorder included non-ischaemic 289 cardiomyopathy all cause heart failure (Table S2). Similar to diabetes, the individuals with 3-4.9% 290 m.3243A>G levels did not have a statistically significant increased risk of having any one disorder or 291 any two disorders (fisher exact test p>0.1). However the association became significant with 292 increasing heteroplasmy and, compared to non-carriers, individuals with ≥10% m.3243A>G 293 heteroplasmy had a higher chance of having any one disorder (OR 2.75, 95% CI [0.71-9.52], p=0.076), 294 increasing to 24.8 (95% CI [8.1-75.7], p<5.1x10<sup>-8</sup>) for any two disorders and 53.50 (95% CI [11.78-295 199.93], p<3.5x10<sup>-6</sup>) for any three or more disorders (p heterogeneity 0.01) (Figure 2B). Although the 296 risk of multiple features was high compared to non-carriers, it proportionally affected only a small 297 number of total m.3243A>G carriers (n=83); 23% (n=19) with one disorder, 18% (n=15) with two 298 disorders and 7% (n=6) with three or more, which increased with higher heteroplasmy (Figure 2C). 299 This indicates that mutation load is an important factor in the expressivity of these multi-system 300 traits in the unselected population.





312

#### 313 Age-related penetrance of diabetes is lower in unselected populations with m.3243A>G compared

#### 314 to clinically selected diabetes cohorts

315 Penetrance estimates based on clinically selected probands are often overinflated for nuclear

316 monogenic disorders (19). However, this ascertainment effect has not been explored in detail for the

- 317 m.3243A>G variant. We therefore compared the penetrance of diabetes in the UKB to 95 probands
- 318 with diabetes and m.3243A>G, identified from routine diabetes clinics (Tables S19-11). The
- penetrance of diabetes was 96% (95% CI [90-98]) at age 50 in probands, compared to 15% (95% CI
- 320 8.5-26) for carriers in the UKB (log rank test p=3x10<sup>-37</sup>) (Figure S2). The penetrance remained lower
- at 42% (95% CI [23-69]) even when considering individuals with >10% heteroplasmy in the UKB

322 compared to proband individuals ( $p=1x10^{-9}$ ). The measured m.3243A>G level was higher in probands 323 compared to UKBB (median 7.8 vs 24.6, Figure S1). Therefore, to assess whether the difference in 324 penetrance is explained by difference in m.3243A>G level, we conducted cox proportional hazard 325 model after adjustment for measured m.3243A>G heteroplasmy, age at recruitment, sex, and body 326 mass index (BMI). We found that risk of diabetes in the UKB for individuals with >10% heteroplasmy 327 still remained lower compared to probands (adjusted HR 0.55, 95% CI [0.43-0.7], p=9x10<sup>-7</sup>) (Table 328 S11). We observed consistent results using calculated age-adjusted heteroplasmy based on 329 published equation (35) (Table S11). These data suggest that there are additional factors modify the 330 penetrance of diabetes in addition to m.3243A>G levels. 331 332 Type 2 diabetes genetic risk score (T2DGRS) alters penetrance of diabetes with m.3243A>G. 333 We hypothesized that nuclear polygenic risk might modify m.3243A>G-related diabetes as seen in nuclear monogenic disorders (36). We found that the risk of any diabetes at 50 years increased from 334

335 5% (95% CI [1-29]) to 14% (95% CI [4-46]) and 29% (95% CI [14-53]) for m.3243A>G carriers for

people with low, medium, and high tertiles of T2DGRS, respectively (Figure 3). This effect was in the

337 same direction after adjusting for m.3243A>G heteroplasmy, age, sex, and mitochondrial copy

number (mtCN) with the risk of diabetes in carriers increasing by 1.62-fold (95% CI [0.97-2.7],

p=0.06) per 1 SD increase in T2DGRS in m.3243A>G carriers. The impact of T2DGRS on diabetes

340 penetrance was similar to that of non-carriers (interaction p=0.9). Importantly, this borderline

341 association was maintained with a partitioned T2DGRS representing beta cell dysfunction (HR 1.1,

342 95% CI [1-1.2], p=0.04) but not with other non-beta cell partitioned GRS (data not shown). This

343 supports the current understanding that beta cell dysfunction is a primary cause of diabetes in

344 m.3243A>G individuals (37).



Figure 3 – Penetrance of diabetes for individuals with pathogenic *m.3243A>G* variants in an unselected cohort.
Kaplan-Meier survival curves of diabetes for m.3243A>G carriers split into tertiles (low, mid, and high) of type
2 diabetes genetic risk score (T2DGRS) and non-carriers (n=178,340) in the UK Biobank. The log rank test p
value for low vs mid and low vs high groups was 0.39 and 0.03, respectively.

349

#### 350 Most previously reported pathogenic variants are rare in a population cohort.

- We next assessed the frequency and association of known pathogenic variants on our 15
   mitochondrial-related traits. Of 73 well-characterised known pathogenic variants, 13 were not
- present in UKB (17.81%), 35 were very rare with a frequency of <1:35973 (n≤5 carriers), 17 with a
- 354 frequency between 1:8994-29977 (n=6-20 carriers), five with a frequency between 1:1799-8565
- 355 (n=21-100 carriers; m.1494C>T, m.3243A>G, m.3460G>A, m.8344A>G, m.8969G>A), and three with
- 356 a frequency >1:1400 (m.11778G>A, n=123 carriers; m.14484T>C, n=190 carriers; m.1555A>G, n=514
- 357 carriers) (Figure 4, Table S4). Variants causing deafness were most common at 1:263 people (n=684)
- 358 followed by Leber hereditary optic neuropathy (LHON) disease-causing variants at 1:439 (n=410)
- although even the move common variants showed very few affected participants, except form.3243A>G (Table 2).
- 361
- 362
- 363

Pathogenic Variant	Phenotype	Phenotype frequency	Phenotype frequency in
(disease)	assessed in UKB	in carriers (%)	non-carriers (%)
m.3243A>G (MIDD)	Diabetes	24/83 (28.92)	16362/179867 (0.09)
m.1555A>G (deafness)	Hearing aid use	19/514 (3.7)	6193/179438 (3.45)
m.14484T>C (LHON)	Bilateral visual loss	0/190	124/179762 (0.07)
m.11778G>A (LHON)	Bilateral visual loss	0/123	124/179829 (0.07)
m.1494C>T (Deafness)	Hearing aid use	0/53	6212/179899 (3.45)
m.3460G>A (LHON)	Bilateral visual loss	0/24	124/179928 (0.07)
m.8344A>G (Epilepsy)	Epilepsy	0/22	2635/179929 (1.46)

Table 2: Penetrance of relevant phenotype in carriers of 6 most common pathogenic variants in UKB.

365 MIDD=Maternally inherited diabetes and deafness. LHON= Leber hereditary optic neuropathy.

366

367 Most of the variants were too rare to perform statistically well-powered single variant analysis.

368 However, for the seven variants (except m.3243A>G) where we had >20 individuals in the EUR-like

369 ancestry cohort, we did not observe association with the mitochondrial-related traits at a

Bonferroni-corrected threshold (p<0.0006) (Table S12). We also did not observe association with the

371 respective traits when variants were aggregated by disease-associated phenotypes. The penetrance

of relevant traits for these variants were very low and ranged from 0-3.7%.



373

374 Figure 4 – Minor allele frequency (%) of pathogenic mitochondrial variants in the UKB A The five most

375 common variants **B** Variants (n) grouped by disease **C** The remaining 50 variants present in the UK Biobank.

376 LHON=Leber hereditary optic neuropathy; MIDD=Maternally inherited diabetes and deafness (note:

377 mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) and other phenotypes are
 378 also associated with this variant); SLE=Stroke-like episodes.

379

# 380 **Discussion**

381 Our study demonstrates that large-scale WGS data offer an exciting opportunity to study the role of

382 mitochondria in human health. This approach can identify important mitochondrial variants and

provide novel insights which may lead to the possibility of reporting mitochondrial variants

384 discovered incidentally.

385 Population studies allow a unique opportunity to assess the frequency of pathogenic variants which

386 have been previously identified in cohorts referred because of presenting diseases. The m.3243A>G

variant is the most common cause of adult mitochondrial disease and due to its heteroplasmic

388 nature it is absent from whole genome data derived from genotyping arrays. Here we used WGS

data to accurately genotype m.3243A>G carriers in a population cohort of ~180,000 participants and

identified 83 cases with heteroplasmy ≥3% in blood (1 in 2167). This frequency may be an

underestimate as it is well known that blood heteroplasmy reduces with age (35) and the mean age

of our cohort was 56.89 years (n=179,862; SD=8.1, range 38.83-72.92). Previous attempts at

identifying population frequency have been limited to small, and/or selected cohorts, with estimates

394 ranging from 0.017-1.69% (38, 39, 40, 41, 42, 43).

395 We were surprised to find only one variant (m.3243A>G) associated with diabetes despite having

396 large numbers of people with diabetes in our cohort. We observe that penetrance in the unselected

397 population increased with m.3243A>G level, reaching 42% at age 50 for people with measured

heteroplasmy of  $\geq 10\%$  (age adjusted heteroplasmy ~45%). The risk ratio of diabetes at  $\geq 10\%$ 

heteroplasmy (age-adjusted heteroplasmy ~45%) is comparable to that of pathogenic variants in

400 well-known monogenic diabetes genes in the same cohort, as we previously published (19).

401 Although heteroplasmy was a major factor affecting penetrance, we also identify that polygenic risk

402 of type 2 diabetes can also modify the penetrance. These results will need to be replicated in larger

403 cohorts but demonstrate an exciting interplay between nuclear and mitochondrial genome variants

404 responsible for the onset of diabetes in humans. The observation of lower penetrance in an

405 unselected population, compared to a clinically ascertained cohort, has also been recently reported

406 in nuclear monogenic diabetes (19) and in mitochondrial disorders such as LHON (44).

407 Despite the large sample size and examining 15 mitochondrial-related traits the only trait where we
 408 have shown multiple mitochondrial variants association is AST. We identified 12 mtDNA variants

409 associated with AST levels, nine of which were previously reported in the same cohort when these 410 variants were called from genotyping array data (13). The novel lead variant m.13488C>T also 411 showed an association with ALT, suggesting that these variants are likely to increase AST level by 412 their effect on the liver, rather than on the heart or skeletal muscle, which can also be sources of 413 AST. The effect size on AST was small, and the lack of association with NAFLD suggests that the high 414 AST level was not due to hepatocellular damage/leakage but may reflect a rise in mitochondrial AST 415 isoform rather than cytoplasmic AST (45, 46). Mitochondrial dysfunction has been reported to play a 416 significant role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD; for review, see (47)). 417 However, we did not identify any genome-wide significant association with NAFLD. Despite a sample size that was substantially larger, we were unable to replicate the previous borderline (p=0.06) 418 419 association of m.16318A>C (p=0.38) (48). The original finding may be a false-positive due to the 420 small sample size ( $n^{300}$ ), but the disparity could also be explained by less well-defined phenotype 421 capture in UKB and a reduced effect size in a non-clinically ascertained cohort.

422 Ours is the largest study of mitochondrial variants based on whole genome sequence data. This 423 provides unique opportunity to assess the population frequency of pathogenic variants which help 424 to better understand the burden of mitochondrial disease in population. We found that most 425 variants were rare in population in line with them causing rare mitochondrial disorders except for 426 some variants causing deafness (m.1555A>G, MAF=0.0014; m.1494C>T, MAF=0.00014) and LHON 427 (m.14484T>C, MAF=0.0005; m.11778G>A, MAF=0.0003). Both m.1555A>G and m.1494C>T cause 428 deafness only after exposure to aminoglycoside antibiotics, which may explain why we failed to 429 detect an association with deafness with either in isolation or when combined (49). We also did not 430 observe an association with bilateral vision loss for the LHON variants (n=10) identified. This may be 431 due to a combination of the lower sample size of bilateral vision loss in our cohort (n=140) and the 432 well-known low penetrance of the LHON variants in the unselected population (50). Although we 433 used mitochondrial-related traits, our phenotypes were more general and may have overshadowed 434 the specific phenotype of mitochondrial-related diseases (such as stroke-like episodes vs. all strokes 435 (51)). This, along with the low number of pathogenic variants and despite our large cohort, may 436 explain the lack of association of known pathogenic variants in our study.

437 Our study has some limitations. Although our study was one of the largest to assess mitochondrial438 wide association, we were still limited in power for non-European-like ancestry populations.

439 Similarly, it is known that the UK Biobank has a healthy volunteer selection bias which is not fully

- 440 representative of the UK population (52) and may have therefore limited the inferences we can
- 441 make about multisystem disease. Our stringent sample and variant filter criteria mean that it is
- 442 possible that we may have excluded true causal or associated variants with these 15 mitochondrial-

443 related traits. However, these stringent criteria allowed us to investigate the association of low level 444 heteroplasmy. This was particularly important for m.3243A>G, which is commonly considered to be 445 present in blood with a heteroplasmy  $\geq$ 3% (35, 53, 54). Some of the phenotypes we assessed had a 446 lower sample size (e.g. bilateral vision loss), which will have limited our ability to robustly assess any 447 associations and would require larger sample sizes to better perform association discovery. We also 448 limited our analysis to single nucleotide variants and small insertions/deletions and did not assess 449 larger deletions, which have been implicated in mitochondrial disease. Additionally, we only used 450 heteroplasmy identified from whole blood samples, which may not reflect heteroplasmy in other 451 tissues or organs that are more relevant to specific mitochondrial diseases.

452 Our study has important implications for the incidental identification of pathogenic mitochondrial 453 variants. Diagnostic molecular genetic laboratories are moving towards using whole-genome 454 sequencing as a first-line genetic test. This, along with a rapid rise in direct-to-consumer testing and 455 use of WGS for research, provides an exciting opportunity to obtain information on pathogenic 456 mitochondrial variants, well before any disease onset. We show that, when detected incidentally 457 from blood, measured m.3243A>G heteroplasmy  $\geq$ 10% (age-adjusted heteroplasmy  $\sim$ 45%) 458 significantly increases the risk of diabetes, heart failure, deafness, and that individuals with this level or greater are more likely to experience multiple system disorders. Our findings, combined with the 459 460 growing availability of prenatal testing for mitochondrial disease, indicate that reporting of 461 m.3243A>G variant when discovered incidentally could have a significant health benefit, particularly 462 for female individuals of reproductive age. If one decides to report this variant when found 463 incidentally, our data suggest that this may be beneficial to individuals with age-adjusted 464 heteroplasmy levels over 45%. However, further studies in unselected population(s) will be needed 465 to refine this advice.

466

## 467 Data and Code Availability

The data supporting the findings of this study are available within the article and its Supplementary Data files. Additional information for reproducing the results described in the article is available upon reasonable request and subject to a data use agreement. The UK Biobank dataset is available from <a href="https://biobank.ctsu.ox.ac.uk">https://biobank.ctsu.ox.ac.uk</a>.

472

## 473 Acknowledgements

474 This research has been conducted using the UK Biobank Resource. This work was carried out under 475 UK Biobank project number 9072. The current work is funded by Diabetes UK (19/0005994 and 476 21/0006335), MRC (MR/T00200X/1) and Wellcome Trust's Institutional Strategic Support Fund 477 awarded to University of Exeter. KAP is funded by Wellcome Trust (219606/Z/19/Z), ATH is 478 supported by Wellcome Trust Senior Investigator award (WT098395/Z/12/Z) and SJP is funded by 479 the Wellcome Career Re-entry Fellowship (204709/Z/16/Z) and the Wellcome Centre for 480 Mitochondrial Research (203105/Z/16/Z). The work is supported by the National Institute for Health 481 Research (NIHR) Exeter Biomedical Research Centre, Exeter, UK. The Wellcome Trust, MRC and NIHR 482 had no role in the design and conduct of the study; collection, management, analysis, and 483 interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed are those of the author(s) and not 484 485 necessarily those of the Wellcome Trust, Department of Health, NHS or NIHR. For the purpose of 486 open access, the author has applied a CC BY public copyright licence to any Author Accepted 487 Manuscript version arising from this submission. 488 489 **Declaration of Interests** 490 The authors declare no competing interests. 491 492 References 493 1. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, et al. Mitochondrial 494 diseases. Nat Rev Dis Primers. 2016;2:16080. 495 2. Thompson K, Collier JJ, Glasgow RIC, Robertson FM, Pyle A, Blakely EL, et al. Recent advances

in understanding the molecular genetic basis of mitochondrial disease. Journal of Inherited
Metabolic Disease. 2020;43(1):36-50.

498 3. Li D, Liang C, Zhang T, Marley JL, Zou W, Lian M, et al. Pathogenic mitochondrial DNA

499 3243A>G mutation: From genetics to phenotype. Front Genet. 2022;13:951185.

500 4. Bernardino Gomes TM, Ng YS, Pickett SJ, Turnbull DM, Vincent AE. Mitochondrial DNA

disorders: from pathogenic variants to preventing transmission. Hum Mol Genet. 2021;30(R2):R245r53.

503 5. Brandon MC, Lott MT, Nguyen KC, Spolim S, Navathe SB, Baldi P, et al. MITOMAP: a human 504 mitochondrial genome database--2004 update. Nucleic Acids Res. 2005;33(Database issue):D611-3.

505 6. Reardon W, Ross RJ, Sweeney MG, Luxon LM, Pembrey ME, Harding AE, et al. Diabetes 506 mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet. 507 1992;340(8832):1376-9. 508 Kraja AT, Liu C, Fetterman JL, Graff M, Have CT, Gu C, et al. Associations of Mitochondrial 7. 509 and Nuclear Mitochondrial Variants and Genes with Seven Metabolic Traits. Am J Hum Genet. 510 2019;104(1):112-38. 511 Calabrese C, Pyle A, Griffin H, Coxhead J, Hussain R, Braund PS, et al. Heteroplasmic 8. 512 mitochondrial DNA variants in cardiovascular diseases. PLOS Genetics. 2022;18(4):e1010068. 513 9. Hudson G, Nalls M, Evans JR, Breen DP, Winder-Rhodes S, Morrison KE, et al. Two-stage 514 association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology. 515 2013;80(22):2042-8. 516 10. Xia C, Pickett SJ, Liewald DCM, Weiss A, Hudson G, Hill WD. The contributions of 517 mitochondrial and nuclear mitochondrial genetic variation to neuroticism. Nat Commun. 518 2023;14(1):3146. 519 Hudson G, Gomez-Duran A, Wilson IJ, Chinnery PF. Recent mitochondrial DNA mutations 11. 520 increase the risk of developing common late-onset human diseases. PLoS Genet. 521 2014;10(5):e1004369. 522 Ng YS, Lim AZ, Panagiotou G, Turnbull DM, Walker M. Endocrine Manifestations and New 12. 523 Developments in Mitochondrial Disease. Endocr Rev. 2022;43(3):583-609. 524 Yonova-Doing E, Calabrese C, Gomez-Duran A, Schon K, Wei W, Karthikeyan S, et al. An atlas 13. 525 of mitochondrial DNA genotype-phenotype associations in the UK Biobank. Nature Genetics. 526 2021;53(7):982-93. 527 14. Børte S, Zwart JA, Skogholt AH, Gabrielsen ME, Thomas LF, Fritsche LG, et al. Mitochondrial 528 genome-wide association study of migraine - the HUNT Study. Cephalalgia. 2020;40(6):625-34. 529 15. Aboulmaouahib B, Kastenmüller G, Suhre K, Zöllner S, Weissensteiner H, Prehn C, et al. First 530 mitochondrial genome-wide association study with metabolomics. Hum Mol Genet. 531 2022;31(19):3367-76. 532 16. Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Gianotti TF, et al. Mitochondrial genome 533 architecture in non-alcoholic fatty liver disease. J Pathol. 2016;240(4):437-49. 534 17. Han X, Souzeau E, Ong JS, An J, Siggs OM, Burdon KP, et al. Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies. JAMA 535 536 Ophthalmol. 2019;137(1):28-35.

537 18. Patel AP, Dron JS, Wang M, Pirruccello JP, Ng K, Natarajan P, et al. Association of Pathogenic 538 DNA Variants Predisposing to Cardiomyopathy With Cardiovascular Disease Outcomes and All-Cause 539 Mortality. JAMA Cardiol. 2022;7(7):723-32. 540 19. Mirshahi UL, Colclough K, Wright CF, Wood AR, Beaumont RN, Tyrrell J, et al. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected 541 542 cohorts. Am J Hum Genet. 2022;109(11):2018-28. 543 Laricchia KM, Lake NJ, Watts NA, Shand M, Haessly A, Gauthier L, et al. Mitochondrial DNA 20. 544 variation across 56,434 individuals in gnomAD. Genome Res. 2022;32(3):569-82. 545 Halldorsson BV, Eggertsson HP, Moore KHS, Hauswedell H, Eiriksson O, Ulfarsson MO, et al. 21. 546 The sequences of 150,119 genomes in the UK Biobank. Nature. 2022;607(7920):732-40. 547 22. Venner E, Muzny D, Smith JD, Walker K, Neben CL, Lockwood CM, et al. Whole-genome 548 sequencing as an investigational device for return of hereditary disease risk and pharmacogenomic 549 results as part of the All of Us Research Program. Genome Medicine. 2022;14(1):34. 550 23. González MDM, Ramos A, Aluja MP, Santos C. Sensitivity of mitochondrial DNA 551 heteroplasmy detection using Next Generation Sequencing. Mitochondrion. 2020;50:88-93. 552 Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource 24. 553 with deep phenotyping and genomic data. 554 Ng YS, Bindoff LA, Gorman GS, Klopstock T, Kornblum C, Mancuso M, et al. Mitochondrial 25. 555 disease in adults: recent advances and future promise. Lancet Neurol. 2021;20(7):573-84. 556 26. Battle SL, Puiu D, Group TOmW, Verlouw J, Broer L, Boerwinkle E, et al. A bioinformatics 557 pipeline for estimating mitochondrial DNA copy number and heteroplasmy levels from whole 558 genome sequencing data. NAR Genomics and Bioinformatics. 2022;4(2):lgac034. 559 27. Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling Somatic SNVs and 560 Indels with Mutect2. bioRxiv. 2019:861054. 561 28. Mn W, L J, Jw H, Ks R, J T, At H, et al. Use of SNP chips to detect rare pathogenic variants: 562 retrospective, population based diagnostic evaluation. BMJ. 2021;372:n214. 563 29. Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. Genome-wide trans-564 ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46(3):234-44. 565 566 30. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 567

568 diabetes. Nat Genet. 2012;44(9):981-90.

31. Udler MS, Kim J, von Grotthuss M, Bonàs-Guarch S, Cole JB, Chiou J, et al. Type 2 diabetes
genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft
clustering analysis. PLoS Med. 2018;15(9):e1002654.

Singh R, Ellard S, Hattersley A, Harries LW. Rapid and sensitive real-time polymerase chain
reaction method for detection and quantification of 3243A>G mitochondrial point mutation. J Mol
Diagn. 2006;8(2):225-30.

575 33. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al.

576 Computationally efficient whole-genome regression for quantitative and binary traits. Nature
577 Genetics. 2021;53(7):1097-103.

578 34. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant
579 Effect Predictor. Genome Biology. 2016;17(1):122.

35. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, et al. mtDNA heteroplasmy level
and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO Molecular
Medicine. 2018;10(6):e8262.

583 36. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic
584 scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat
585 Genet. 2018;50(9):1219-24.

586 37. Lindroos MM, Majamaa K, Tura A, Mari A, Kalliokoski KK, Taittonen MT, et al. m.3243A>G
587 mutation in mitochondrial DNA leads to decreased insulin sensitivity in skeletal muscle and to
588 progressive beta-cell dysfunction. Diabetes. 2009;58(3):543-9.

589 38. Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, Kärppä M, et al. Epidemiology

of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike

episodes: prevalence of the mutation in an adult population. Am J Hum Genet. 1998;63(2):447-54.

592 39. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochondrial DNA

593 mutations are common in the general population. Am J Hum Genet. 2008;83(2):254-60.

40. Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, Mitchell P, et al. Population
prevalence of the MELAS A3243G mutation. Mitochondrion. 2007;7(3):230-3.

596 41. Odawara M, Sasaki K, Yamashita K. Prevalence and clinical characterization of Japanese

diabetes mellitus with an A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA(Leu(UUR))

598 gene. J Clin Endocrinol Metab. 1995;80(4):1290-4.

599 42. Bouhaha R, Abid Kamoun H, Elgaaied A, Ennafaa H. A3243G mitochondrial DNA mutation in
600 Tunisian diabetic population. Tunis Med. 2010;88(9):642-5.

43. Wang S, Wu S, Zheng T, Yang Z, Ma X, Jia W, et al. Mitochondrial DNA mutations in diabetes
mellitus patients in Chinese Han population. Gene. 2013;531(2):472-5.

21

44. Mackey DA, Ong JS, MacGregor S, Whiteman DC, Craig JE, Lopez Sanchez MIG, et al. Is the
disease risk and penetrance in Leber hereditary optic neuropathy actually low? Am J Hum Genet.
2023;110(1):170-6.

45. Jiang X, Chang H, Zhou Y. Expression, purification and preliminary crystallographic studies of
human glutamate oxaloacetate transaminase 1 (GOT1). Protein Expr Purif. 2015;113:102-6.

608 46. Glinghammar B, Rafter I, Lindström AK, Hedberg JJ, Andersson HB, Lindblom P, et al.

609 Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues

610 and plasma. Int J Mol Med. 2009;23(5):621-31.

47. Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, et al.

612 Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci. 2021;22(9).

48. Hasturk B, Yilmaz Y, Eren F. Potential clinical variants detected in mitochondrial DNA D-loop

614 hypervariable region I of patients with non-alcoholic steatohepatitis. Hormones (Athens).

615 2019;18(4):463-75.

616 49. Ealy M, Lynch KA, Meyer NC, Smith RJH. The prevalence of mitochondrial mutations

617 associated with aminoglycoside-induced sensorineural hearing loss in an NICU population. The

618 Laryngoscope. 2011;121(6):1184-6.

50. Lopez Sanchez MIG, Kearns LS, Staffieri SE, Clarke L, McGuinness MB, Meteoukki W, et al.

620 Establishing risk of vision loss in Leber hereditary optic neuropathy. Am J Hum Genet.

621 2021;108(11):2159-70.

51. Ng YS, Bindoff LA, Gorman GS, Horvath R, Klopstock T, Mancuso M, et al. Consensus-based
statements for the management of mitochondrial stroke-like episodes. Wellcome Open Res.
2019;4:201.

625 52. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of

626 Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the

627 General Population. Am J Epidemiol. 2017;186(9):1026-34.

Mavraki E, Labrum R, Sergeant K, Alston CL, Woodward C, Smith C, et al. Genetic testing for
mitochondrial disease: the United Kingdom best practice guidelines. Eur J Hum Genet.

630 2023;31(2):148-63.

631 54. de Laat P, Janssen MC, Alston CL, Taylor RW, Rodenburg RJ, Smeitink JA. Three families with
632 'de novo' m.3243A > G mutation. BBA Clin. 2016;6:19-24.

633